VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sardar Biglari Sells 6,533 Shares of Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 6,533 shares of the company’s stock in a transaction on Wednesday, July 15th. The stock was sold at an average price of $16.71, for a total transaction of $109,166.43. Following the completion of the sale, the insider owned 3,552,710 shares of the company’s stock, valued at $59,365,784.10. This represents a 0.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.70, for a total transaction of $45,908.30.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.73, for a total value of $20,260.03.

VanEck Biotech ETF Trading Up 1.1%

BBH opened at $206.25 on Friday. The stock has a 50-day moving average of $192.67 and a 200-day moving average of $191.86. VanEck Biotech ETF has a 52-week low of $154.75 and a 52-week high of $212.54.

Institutional Investors Weigh In On VanEck Biotech ETF

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. grew its holdings in VanEck Biotech ETF by 40,463.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock valued at $93,506,000 after purchasing an additional 492,843 shares during the last quarter. Raymond James Financial Inc. lifted its stake in shares of VanEck Biotech ETF by 2.8% in the third quarter. Raymond James Financial Inc. now owns 69,809 shares of the company’s stock worth $11,566,000 after buying an additional 1,869 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of VanEck Biotech ETF by 44.3% during the 1st quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock worth $12,473,000 after buying an additional 20,375 shares during the period. Ascent Advisors LLC bought a new stake in shares of VanEck Biotech ETF during the 1st quarter worth $11,178,000. Finally, LPL Financial LLC grew its stake in VanEck Biotech ETF by 63.5% in the 4th quarter. LPL Financial LLC now owns 31,813 shares of the company’s stock valued at $6,021,000 after buying an additional 12,351 shares during the last quarter. 32.05% of the stock is currently owned by institutional investors and hedge funds.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.